Lisdexamfetamine Dimesylate Tablet, Chewable
Product Images NDC 0480-9737

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 0480-9737). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

Chemical structure of lisdexamfetamine dimesylate showing its molecular components and arrangement, including amino groups and a sulfonic acid moiety.*

FDA Label Image

1 (Image 10)

Packaging label for lisdexamfetamine dimesylate 10 mg chewable tablets by Teva Pharmaceuticals, Inc. The label states 100 chewable tablets per container, instructs to chew tablets completely before swallowing, and emphasizes dispensing the accompanying medication guide. Storage and dosage information are referenced on the package insert.*

FDA Label Image

1 (Image 11)

Label for Lisdexamfetamine Dimesylate Chewable Tablets 20 mg by Teva Pharmaceuticals, Inc. The label specifies the dosage form as chewable tablets with a package count of 100 tablets. It includes storage instructions, dosage guidance to refer to the package insert, and emphasizes that the product is prescription only. The label also features the NDC 0480-9738-01 and manufacturer details from Parsippany, NJ.*

FDA Label Image

1 (Image 12)

Label for Lisdexamfetamine Dimesylate Chewable Tablets 30 mg by Teva Pharmaceuticals, Inc. The label includes dosing instructions to chew tablets completely before swallowing and a note for pharmacists to dispense the Medication Guide. The package contains 100 chewable tablets with storage instructions and a barcode.*

FDA Label Image

1 (Image 13)

Lisdexamfetamine Dimesylate Chewable Tablets 40 mg oral tablets label from Teva Pharmaceuticals, Inc. The label includes instructions to chew tablets completely before swallowing, pharmacist dispensing guidance, storage conditions, dosage information, and safety warnings. The package contains 100 chewable tablets.*

FDA Label Image

1 (Image 14)

Lisdexamfetamine dimesylate 50 mg chewable tablets label by Teva Pharmaceuticals, Inc. The label states the dosage form as chewable tablets with a quantity of 100. It includes instructions to chew tablets completely before swallowing, a pharmacist dispensing note, and storage directions between 20° to 25°C. The label also contains the NDC number 0480-9742-01 and manufacturer information.*

FDA Label Image

1 (Image 15)

Label for Lisdexamfetamine Dimesylate Chewable Tablets 60 mg by Teva Pharmaceuticals, Inc. The white label shows product name, dosage strength (60 mg), and instructions to chew tablets completely before swallowing. It includes storage instructions, lot and expiration sections, and packaging information for 100 chewable tablets. The Teva logo is at the bottom right.*

FDA Label Image

1 (Image 2)

A chart showing fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC in special populations of lisdexamfetamine dimesylate. Categories include gender, age groups (65-74 years, >=75 years), and renal impairment levels (mild, moderate, severe, end stage renal disease), with data points indicating changes relative to reference values.*

FDA Label Image

1 (Image 3)

A forest plot chart illustrating the fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of lisdexamfetamine dimesylate when co-administered with guanfacine, venlafaxine, and omeprazole. The x-axis shows the change relative to reference, ranging from 0.0 to 2.0, with data points clustered near 1.0.*

FDA Label Image

1 (Image 4)

A scatter plot with error bars showing pharmacokinetic (PK) data on fold change and 90% confidence intervals for various interacting drugs, including Guanfacine, Venlafaxine, Caffeine (CYP1A2 substrate), Dextromethorphan (CYP2D6 substrate), Omeprazole (CYP2C19 substrate), and Midazolam (CYP3A substrate). The x-axis represents change relative to reference from 0.0 to 2.0 for Cmax and AUC parameters.*

FDA Label Image

1 (Image 5)

A line graph comparing LS Mean (SE) SKAMP Deportment Scores over time post-dose in hours for Lisdexamfetamine Dimesylate versus Placebo. The graph shows two lines, one solid for Lisdexamfetamine Dimesylate and one dashed for Placebo, with error bars indicating variability at each time point.*

FDA Label Image

1 (Image 6)

A line graph comparing the proportion of subjects with relapse or treatment failure over time (days after randomization) between SPD489 and placebo groups. The y-axis represents the percentage of affected subjects, and the x-axis shows days up to 55. The placebo group shows a higher proportion of relapse over time compared to the SPD489 group.*

FDA Label Image

1 (Image 7)

A line graph showing LS Mean (SE) PERMP Total Scores over time post-dose in hours for lisdexamfetamine dimesylate compared with placebo. The X-axis represents time from -0.5 to 14 hours post-dose, and the Y-axis shows score values from 250 to 330. Lisdexamfetamine dimesylate shows higher scores than placebo across the time points.*

FDA Label Image

1 (Image 8)

A line graph depicting the proportion of subjects with relapse or treatment failure over time (days after randomization) comparing lisdexamfetamine dimesylate and placebo. The x-axis shows time in days up to 40, and the y-axis shows the percentage of subjects with relapse or treatment failure, ranging from 0% to 100%. Lisdexamfetamine dimesylate shows a consistently lower relapse rate compared to placebo.*

FDA Label Image

1 (Image 9)

A line graph comparing the proportion of subjects with relapse over time (days after randomization) between lisdexamfetamine dimesylate and placebo groups. The x-axis shows time from 0 to over 200 days, and the y-axis shows the proportion of subjects with relapse percentage. The graph includes numbers of subjects at risk at different time points for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.